Smart dosing: tailoring cancer drug levels could extend life for colorectal patients

NCT ID NCT06642844

Recruiting now Disease control Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adjusting the dose of bevacizumab based on each patient's drug levels can better control metastatic colorectal cancer. About 244 people will receive either standard or personalized dosing alongside chemotherapy. The main goal is to see if personalized dosing delays cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin)
What this could lead to: If successful, this could show that tailoring bevacizumab dose to individual drug levels improves how long the cancer is kept under control.
What could go wrong: This is a Phase 3 trial, but personalized dosing adds complexity and may not improve outcomes over standard dosing. Side effects of bevacizumab, like bleeding or high blood pressure, remain a risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE/METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

BORG
RECRUITING

Besançon, France
Caroline Petorin
NOT_YET_RECRUITING

Clermont-Ferrand, France
David Tougeron
RECRUITING

Poitiers, France
Ducreux
NOT_YET_RECRUITING

Gustave Roussy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.